Although landmark trials such as EMPA-REG OUTCOME prompted early adoption of SGLT2 inhibitors by showing cardiovascular and heart-failure advantages in high-risk populations [3,5], subsequent real-world studies—including our present Japanese cohort—largely report macro-vascular equivalence to metformin, with at best an inconsistent heart-failure signal [21,22]. Here, SLC5A2 is linked to heart failure.